TrialNature communications2026

Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial.

Li-Chuan Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.